At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SEER Seer, Inc.
Pre-Market Trading 12-23 05:30:32 EST
2.31
-0.01
-0.43%
High2.37
Low2.28
Vol218.67K
Open2.31
D1 Closing2.32
Amplitude3.66%
Mkt Cap136.21M
Tradable Cap99.21M
Total Shares58.97M
T/O507.06K
T/O Rate0.51%
Tradable Shares42.95M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Seer (NASDAQ:SEER) Is In A Good Position To Deliver On Growth Plans
SEER PARTNERS WITH DEVVSTREAM TO MONETIZE INSURED CARBON CREDITS ARISING OUT OF METHANE RENEWABLE ENERGY, CAPTURED OIL FIELD WELL EMISSIONS AND OTHER SEER PROJECTS
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. Seer, Inc. has a collaboration agreement with Oregon Health & Science University; The Broad Institute of MIT and Harvard; Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.